Dow Corning
This article was originally published in The Gray Sheet
Executive Summary
U.S. government will receive $9.8 mil. to cover certain Medicare costs related to treatment of women with Dow Corning silicone-gel filled breast implants under a settlement approved by Judge Denise Page Hood of the eastern district of Michigan U.S. bankruptcy court. The funds will come from the firm's broader $3.2 bil. implant liability settlement fund, approved in 1999. Payouts are expected to begin in mid-2003, according to Dow Corning, which declared bankruptcy in 1995. The payouts cannot go forward until Dow Corning is assured that other claimants will not sue separately and that the firm is released from independent liability...
You may also be interested in...
Dow Corning settlement
Nevada breast implant claimants drop suit against parent company Dow Chemical March 19, clearing the way for Dow Corning to complete bankruptcy proceedings. Administrators of the firm's $2.35 bil. silicone gel-filled breast implant liability settlement fund will begin processing claims, releasing checks to claimants by June 15. Dow Corning filed for bankruptcy in 1995. In 2002, a previous obstacle to the payments was removed via settlement with the government - providing $9.8 mil. to cover Medicare claims of women treated for alleged implant-related illnesses (1"The Gray Sheet" Sept. 30, 2002, In Brief)...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.